GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adamas Pharmaceuticals Inc (NAS:ADMS) » Definitions » Cash Flow from Investing

Adamas Pharmaceuticals (Adamas Pharmaceuticals) Cash Flow from Investing : $7.84 Mil (TTM As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Adamas Pharmaceuticals Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2021, Adamas Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $3.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.01 Mil for other investing activities. In all, Adamas Pharmaceuticals spent $3.01 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2021.


Adamas Pharmaceuticals Cash Flow from Investing Historical Data

The historical data trend for Adamas Pharmaceuticals's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adamas Pharmaceuticals Cash Flow from Investing Chart

Adamas Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only -26.71 25.57 -69.34 88.86 54.94

Adamas Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.00 29.91 7.79 -26.85 -3.01

Adamas Pharmaceuticals Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Adamas Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2020 is calculated as:

Adamas Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Sep. 2021 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adamas Pharmaceuticals  (NAS:ADMS) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Adamas Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Sep. 2021 was $0.00 Mil. It means Adamas Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Adamas Pharmaceuticals's sale of property, plant, equipment for the three months ended in Sep. 2021 was $0.00 Mil. It means Adamas Pharmaceuticals gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Adamas Pharmaceuticals's purchase of business for the three months ended in Sep. 2021 was $0.00 Mil. It means Adamas Pharmaceuticals spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Adamas Pharmaceuticals's sale of business for the three months ended in Sep. 2021 was $0.00 Mil. It means Adamas Pharmaceuticals gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Adamas Pharmaceuticals's purchase of investment for the three months ended in Sep. 2021 was $-3.00 Mil. It means Adamas Pharmaceuticals spent {stock_data.stock.currency_symbol}}3.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Adamas Pharmaceuticals's sale of investment for the three months ended in Sep. 2021 was $0.00 Mil. It means Adamas Pharmaceuticals gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Adamas Pharmaceuticals's net Intangibles purchase and sale for the three months ended in Sep. 2021 was $0.00 Mil. It means Adamas Pharmaceuticals paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Adamas Pharmaceuticals's cash from discontinued investing activities for the three months ended in Sep. 2021 was 0.00 Mil. It means Adamas Pharmaceuticals paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Adamas Pharmaceuticals's cash from other investing activities for the three months ended in Sep. 2021 was $-0.01 Mil. It means Adamas Pharmaceuticals paid $0.01 Mil for other investing activities.


Adamas Pharmaceuticals Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Adamas Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Adamas Pharmaceuticals (Adamas Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1900 Powell Street, Suite 1000, Emeryville, CA, USA, 94608
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
Executives
Vijay Shreedhar officer: Chief Commercial Officer C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL STREET, SUITE 1000 EMERYVILLE CA 94608
Christopher B Prentiss officer: Chief Financial Officer 1900 POWELL STREET SUITE 750 EMERYVILLE CA 94608
Anna Richo director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Mardi Dier director C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
William W. Ericson director, 10 percent owner 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
John A Macphee director C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Ivan M Lieberburg director 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Neil F. Mcfarlane officer: Chief Executive Officer C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Alfred G Merriweather officer: Chief Financial Officer
Jennifer J Rhodes officer: CBO, GC & Compliance Officer C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Gregory T Went director, officer: Chief Executive Officer C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE CA 94608
Rajiv Patni officer: Chief Medical Officer C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301

Adamas Pharmaceuticals (Adamas Pharmaceuticals) Headlines

From GuruFocus

Adamas to Present at Upcoming William Blair Biotech Focus Conference

By Business Wire Business Wire 07-08-2021